CEL SCI CORP (CVM) - Dilution Analysis

10-Q filing | 8.1M shares outstanding

8-K filing: CEL-SCI Corporation completed an offering of 6,000,000 shares of common stock at $1.20 per share, raising gross proceeds of $7,200,000. ($7.2M proceeds)

S-1 filing: This S-1 filing includes the registration of common stock and pre-funded warrants.

S-3 filing: This prospectus relates to the possible resale of up to 375,000 shares of our common stock, which were issued in payment for services in connection with our confirmatory Phase III clinical trial.

8-K filing: CEL-SCI Corporation completed an offering of 1,111,200 shares of common stock at $9.00 per share on August 29, 2025, raising gross proceeds of approximately $10,000,800. ($10.0M proceeds)

10-Q filing | 6.9M shares outstanding

8-K filing: CEL-SCI Corporation completed an offering of 1,500,000 shares of common stock at $3.82 per share, resulting in gross proceeds of approximately $5,730,000 before deducting fees and expenses. ($5.73M proceeds)

S-3 filing: CEL-SCI Corporation may offer shares of common stock, preferred stock, convertible preferred stock, rights, warrants, units consisting of one or more of these securities, as well as any of these securities issuable upon conversion of preferred stock or upon the exercise of warrants, at an initial offering price not to exceed $100,000,000.

8-K filing: CEL-SCI Corporation completed an offering of 2,000,000 shares of common stock at a price of $2.50 per share on May 23, 2025, resulting in gross proceeds of $5,000,000 before deducting underwriting discounts and offering expenses. ($5.0M proceeds)

10-Q filing | 91.0M shares outstanding

8-K filing: CEL-SCI Corporation completed an offering on March 18, 2025, issuing 4,012,500 shares of common stock at $0.16 per share and pre-funded warrants to purchase up to 11,987,500 shares at $0.1599 per warrant, resulting in gross proceeds of $2,560,000. ($2.56M proceeds)

10-Q filing | 74.1M shares outstanding

10-K filing | 63.8M shares outstanding

8-K filing: CEL-SCI Corporation completed an offering of 7,552,500 shares of common stock and pre-funded warrants to purchase up to 8,577,500 shares at $0.31 and $0.3099 respectively, with gross proceeds of approximately $5,000,000. ($5.0M proceeds)

S-3/A filing: This is an S-3/A filing dated 2024-10-30. It discusses the offer, sale, and issuance of shares that are exempt from the Securities Act of 1933.

S-3 filing: This is an S-3 filing for the resale of 1,000,000 shares of common stock by a selling shareholder.

POS AM filing: CEL-SCI Corporation may offer from time to time shares of common stock, preferred stock, convertible preferred stock, rights, warrants, units consisting of one or more of these securities, as well as any of these securities issuable upon conversion of preferred stock or upon the exercise of warrants at an initial offering price not to exceed $150,000,000.

S-3/A filing: CEL-SCI Corporation may offer shares of common stock, preferred stock, convertible preferred stock, rights, warrants, units consisting of one or more of these securities, as well as any of these securities issuable upon conversion of preferred stock or upon the exercise of warrants, at an initial offering price not to exceed $150,000,000.

10-Q filing | 54.3M shares outstanding

8-K filing: CEL-SCI Corporation completed an offering of 3,715,000 shares of common stock at $1.00 per share and pre-funded warrants to purchase up to 7,130,000 shares at $0.99 per warrant, closing on July 29, 2024, with gross proceeds of $10,845,000. ($10.77M proceeds)

10-Q filing | 54.1M shares outstanding

10-Q filing | 50.0M shares outstanding

8-K filing: CEL-SCI Corporation closed an offering of 3,875,000 shares of common stock at a price of $2.00 per share on February 13, 2024, resulting in gross proceeds of $7,750,000 before deducting underwriting discounts and other offering expenses. ($7.75M proceeds)

10-K filing | 43.4M shares outstanding

8-K filing: CEL-SCI Corporation completed an offering of 2,490,000 shares of common stock at $2.00 per share, resulting in gross proceeds of $4,980,000 before deducting underwriting discounts and other offering expenses. ($4.98M proceeds)

10-Q filing | 44.7M shares outstanding

8-K filing: CEL-SCI Corporation closed on an underwritten public offering and issued 2,500,000 shares of common stock at a public offering price of $2.00 per share, receiving approximately $4,500,000 in net proceeds. ($4.5M proceeds)

8-K filing: CEL-SCI Corporation entered into an Underwriting Agreement to issue and sell 2,500,000 shares of common stock at $2.00 per share, expecting to receive approximately $4,500,000 in net proceeds. ($5.0M proceeds)

10-Q filing | 43.8M shares outstanding

8-K filing: CEL-SCI Corporation entered into an Underwriting Agreement to issue and sell 794,117 shares of common stock at $1.70 per share, expecting approximately $1,119,000 in net proceeds before an over-allotment option. ($1.35M proceeds)

10-Q filing | 43.4M shares outstanding

10-K filing | 43.1M shares outstanding

10-Q filing | 43.1M shares outstanding

S-3 filing: CEL-SCI Corporation may offer shares of common stock, preferred stock, convertible preferred stock, rights, warrants, or units, up to a total amount of $150,000,000.

POS AM filing: Prospectus for the resale of common stock issuable upon exercise of outstanding warrants by selling shareholders.

10-Q filing | 43.1M shares outstanding

10-Q filing | 43.1M shares outstanding

10-K filing | 40.7M shares outstanding

10-Q filing | 40.2M shares outstanding

8-K filing: The Company agreed to issue and sell 1,400,000 shares of common stock at a public offering price of $22.62 per share. The Underwriters exercised their over-allotment option to purchase 210,000 additional shares of common stock which closed on June 28, 2021, resulting in net proceeds of approximately $4.4 million to the Company. ($4.4M proceeds)

8-K filing: CEL-SCI Corporation entered into an Amended and Restated Underwriting Agreement to issue and sell 1,400,000 shares of common stock at $22.62 per share, with an option for underwriters to purchase an additional 210,000 shares, expecting net proceeds of approximately $29.3 million. ($31.67M proceeds)

10-Q filing | 39.4M shares outstanding

10-Q filing | 38.8M shares outstanding

POS AM filing: This POS AM filing relates to the offering of shares of common stock issuable upon the exercise of outstanding warrants by warrant holders, previously registered under file # 333-229295.

10-K filing | 36.8M shares outstanding

8-K filing: CEL-SCI Corporation entered into an Underwriting Agreement to issue and sell 1,000,000 shares of common stock at $14.65 per share, with an option for underwriters to purchase an additional 150,000 shares to cover over-allotments, with the offering expected to close around December 11, 2020. ($14.65M proceeds)

10-Q filing | 38.6M shares outstanding

S-1 filing: This is an S-1 filing including information on the sales of convertible notes, shares of common stock, and warrants from July 2017 to January 2020.

10-Q filing | 35.6M shares outstanding

POS AM filing: This is a POS AM filing, detailing previous sales of common stock, warrants, and convertible notes.

POS AM filing: This is a POS AM filing including information on recent sales of common stock and warrants.

S-1/A filing: This is an S-1/A filing. The company has sold shares of common stock in registered direct offerings and private placements to officers and directors of the company, and to Ergomed, plc in payment for services.

10-Q filing | 35.1M shares outstanding